



30 Years of Alternative Macrophage Activation—a Simple Complexity

Guest Editor:

Dr. Alexei Gratchev

N.N. Blokhin Cancer Research
Center, Institute of
Carcinogenesis, 115478 Moscow,
Russia

Deadline for manuscript
submissions:

closed (31 December 2022)

Message from the Guest Editor

Dear Colleagues,

Three decades ago, a highly important paper from the lab of Prof. Siamon Gordon appeared in the *Journal of Experimental Medicine*, describing the effects of IL-4 on the expression of the macrophage mannose receptor (*J Exp Med.* 1992 Jul 1;176(1):287-92. doi: 10.1084/jem.176.1.287). This study, which introduced the term “alternative macrophage activation”, became a milestone in immunity research and a foundation for a new concept of macrophage activation. Several years later, alternatively activated macrophages were re-named as type 2 macrophages, and the concept of macrophage activation dichotomy was extended significantly, leading to an explosive growth of studies dedicated to macrophage activation and polarization. Many additional macrophage phenotypes, sub-phenotypes, and activation states were described. Various experimental systems were used to characterize peculiarities of macrophage biology, including macrophage tolerance and macrophage training.

In this issue, we plan to collect the latest advances in macrophage biology research, and to open new horizons by defining new markers as well as diagnostic and therapeutic approaches.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and
Center for Clinical Research
Learning, Spaulding
Rehabilitation Hospital and
Massachusetts General Hospital,
Harvard Medical School, Boston,
MA 02114, USA
2. Department of Epidemiology,
Harvard T.H. Chan School of
Public Health, Boston, MA 02115,
USA

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within *Scopus*, *SCIE (Web of Science)*, *PubMed*, *PMC*, *CAPLus / SciFinder*, and other databases.

Journal Rank: JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q2 (*Medicine (miscellaneous)*)

Contact Us

Biomedicines Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/biomedicines
biomedicines@mdpi.com
X@Biomed_MDPI